LA JOLLA, Calif., June 18, 2026
GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GRI-0621 (tazarotene) for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive and irreversible fibrotic lung disease with limited treatment options. The regulatory designation marks a significant milestone for GRI Bio’s lead clinical program and provides potential incentives including seven years of U.S. market exclusivity upon approval, tax credits for qualified clinical development expenses, waiver of certain FDA application fees, and enhanced regulatory interaction throughout development. The designation follows positive Phase 2a clinical results and supports continued advancement of the investigational oral therapy for patients with high unmet medical need.
FDA Orphan Drug Designation Strengthens Regulatory Pathway
Orphan Drug Designation is awarded to investigational therapies targeting rare diseases affecting fewer than 200,000 people in the United States. For GRI-0621, the designation strengthens the regulatory pathway by offering valuable development incentives that may accelerate commercialization if the therapy is approved. According to GRI Bio, the designation validates the company’s strategy of developing innovative treatments that target the underlying mechanisms of fibrotic and inflammatory diseases. Idiopathic Pulmonary Fibrosis remains one of the most challenging pulmonary disorders, with progressive lung scarring leading to declining respiratory function, poor quality of life, and premature mortality despite currently available antifibrotic therapies.
Phase 2a Trial Demonstrated Positive Clinical Outcomes
GRI-0621 is a once-daily oral RARβ/γ-selective agonist designed to modulate biological pathways involved in inflammation, fibrosis, and tissue repair. The investigational therapy was evaluated in the randomized, double-blind, placebo-controlled Phase 2a GRI-0621-IPF-02 trial (NCT06331624) involving 35 patients with IPF, approximately 80% of whom continued background standard-of-care antifibrotic treatment. The study achieved its primary, secondary, and exploratory endpoints, with additional analyses further supporting previously reported positive findings. The company believes the therapy’s differentiated mechanism could address key drivers of fibrosis beyond currently approved treatment approaches, potentially offering a novel therapeutic option for patients with IPF.
GRI Bio Advances Fibrosis and Autoimmune Disease Pipeline
Advertisement
The FDA Orphan Drug Designation represents an important catalyst for GRI Bio’s broader strategy of developing innovative therapies targeting immune dysregulation, fibrosis, and autoimmune diseases. Beyond GRI-0621, the company is advancing a pipeline of type 2 diverse natural killer T (dNKT) agonists for systemic lupus erythematosus (SLE) and continues to expand its proprietary drug discovery platform with a library of more than 500 compounds. With positive Phase 2a data and regulatory momentum, GRI Bio is positioning GRI-0621 as a potential differentiated oral therapy for Idiopathic Pulmonary Fibrosis while advancing a broader pipeline focused on serious diseases with significant unmet medical needs.
Source: GRI Bio, press release
